Article

Skin Lesions in Patients Treated with BTK Inhibitors

2026-01-01

Abstract excerpt

Bruton's tyrosine kinase (BTK) inhibitors have revolutionized the treatment landscape for patients with indolent lymphoid malignancies such as chronic lymphocytic leukaemia (CLL) and mantle cell lymphoma (MCL). The most common adverse events include cardiac arrhythmia, bleeding, infection, diarrhoea, arthralgias, hypertension and skin changes. Second-generation BTK inhibitors, e.g. acalabrutinib and zanubruti...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 62c22e1f-42e5-5bfa-84d7-9b65b44b123b
DOI: 10.20944/preprints202601.0042.v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Skin Lesions in Patients Treated with BTK InhibitorsDOI 10.20944/preprints202601.0042.v1Read

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future DirectionsSemantic proximity Read

SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Semantic proximity Read

Dermatologic Perspectives on Primary Cutaneous Lymphomas: Clinicopathologic Spectrum, Molecular Insights and Evolving Treatment ParadigmsSemantic proximity Read

Therapeutic Opportunities in Cutaneous T-cell LymphomaSemantic proximity Read

Next-generation Bruton's Tyrosine Kinase (BTK) Inhibitors Potentially Targeting BTK C481S Mutation- Recent Developments and Perspectives.Semantic proximity Read

Palmar bullous blistering induced by erlotinib.Semantic proximity Read

Dermatological adverse events from BRAF inhibitors: a growing problem.Semantic proximity Read

Pirtobrutinib inhibits wild-type and mutant Bruton's tyrosine kinase-mediated signaling in chronic lymphocytic leukemia.Semantic proximity Read

BTK inhibitors in CLL: second-generation drugs and beyond.Semantic proximity Read

A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.Semantic proximity Read

Cutaneous adverse events to type I BRAF inhibitors: an analysis of effects associated with each inhibitor and therapeutic time interval to onset.Semantic proximity Read

BTK Inhibitors and BTK Degraders for the Treatment of Mantle Cell Lymphoma - Current Status and PerspectivesSemantic proximity Read